This week, CancerNetwork® spoke with Christine Chung, DO, of the Swedish Medical Center, Englewood, Colorado, about “Characterization of Blood-Based Molecular Profiling in Pancreatic Adenocarcinoma,” a retrospective review published in the journal ONCOLOGY.

Chung detailed this research, which characterizes the mutational landscape of patients with metastatic pancreatic adenocarcinoma who received blood-based molecular profiling. A total of 77 consecutive patients were included in the analysis.

Chung also spoke about pancreatic adenocarcinoma, the study’s main findings, and how this research can inform future treatment decision-making processes moving forward.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week, CancerNetwork® spoke with Muhammad Niazi, MD, resident in internal medicine at Staten Island University Hospital, and Alexander Bershadskiy, MD, attending physician at Staten Island University Hospital, about a meta-analysis published in ONCOLOGY titled, “Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials.”

The final analysis evaluated 3 randomized clinical trials. A fixed model showed a statistically significant improvement in overall survival for patients with metastatic castration-resistant prostate cancer treated with PARP inhibitors.

The authors provided a detailed background on PARP inhibitors and further detailed the results of this research, focusing on survival increases with PARP inhibitor treatment for this patient population.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

As part of its OncView™ video series, CancerNetwork® spoke with Zofia Piotrowska, MD, an assistant professor of medicine at Harvard Medical School and a lung cancer medical oncologist at Massachusetts General Hospital, about recent data and review updates in the treatment landscape for patients with non-small-cell lung cancer and exon 20 insertions.

In the video series, Piotrowska discussed the following:

·      Overview of Advanced NSCLC with EGFR Mutations Including Exon 20 Insertions

·      Testing for the EGFR Exon 20 Insertion

·      Historical Treatment Approach for EGFR Exon 20 Insertions in NSCLC

·      Amivantamab for the Treatment of EGFR Exon 20 Insertions in NSCLC

·      Mobocertinib for the Treatment of EGFR Exon 20 Insertions in NSCLC

·      Treatment Selection for Patients With EGFR Exon 20 Insertions in NSCLC

·      Unmet Needs and Future Directions

To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

As part of its Between the Lines™ video series, CancerNetwork® spoke with Liliana Bustamante, MD, hematologist and medical oncologist at Florida Cancer Specialists in Fort Myers, Florida and Richard Kim, MD, service chief of Medical Gastrointestinal Oncology and senior member in the Gastrointestinal Oncology Department at the Moffitt Cancer Center in Tampa, Florida, about the prognostic potential of circulating tumor DNA (ctDNA) as a biomarker for patients with oligometastatic colorectal cancer.

In the video series, Bustamante and Kim discussed the following:

·      Presentation: ctDNA Assays For Patients With CRC Undergoing Resection of Metastases

·      Key Takeaways: ctDNA Assays For Patients With CRC Undergoing Resection of Metastases

·      ctDNA as a Biomarker in CRC

·      ctDNA Assays in CRC: Interpreting Clinical Findings

·      ctDNA Assays in CRC: Impact on Clinical Practice

·      Next Steps in Using ctDNA as a Biomarker in CRC

·      Recap: Prognostic Potential of ctDNA for Oligometastatic Colorectal Cancer

To watch more videos in CancerNetwork®’s Between the Lines™ series, visit cancernetwork.com/between-the-lines.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

As part of its OncView™ video series, CancerNetwork® spoke with John Kirkwood, MD, PhD, director of the melanoma center at the University of Pittsburgh Medical Center Hillman Cancer Center, about using immunotherapy for treating melanoma and how to monitor responses in patients properly.

In the video series, Kirkwood discussed the following:

·      Treatment Options for Melanoma

·      Considerations for Immunotherapy Use When Treating Melanoma

·      Monitoring Responses to Melanoma Therapy

·      Pseudoprogression in Melanoma Therapy

·      ctDNA for Melanoma Treatment Monitoring

·      Using ctDNA to Monitor Patients With Melanoma

·      Taking Drug Holidays Amidst Melanoma Therapy

·      Duration of Treatment for Melanoma

To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

As part of its OncView™ video series, CancerNetwork® spoke with Roy Herbst, MD, PhD, chief of medical oncology at Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut, about currently available treatment options and strategies in immunotherapy for treating non–small cell lung cancer (NSCLC).

In the video series, Herbst discussed the following:

·      Treatment Options in Non–Small Cell Lung Cancer

·      Monitoring Response to Therapy in NSCLC

·      Role of ctDNA in Monitoring Treatment Response in NSCLC

·      Clinical Decision-Making in NSCLC

·      Recap: Monitoring With ctDNA for Immunotherapy Response in Lung Cancer

To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week, CancerNetwork spoke with Matthew Matasar, MD, a lymphoma specialist and chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center Bergen, about research from the December issue of ONCOLOGY titled, “Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab.”

The retrospective, observational analysis examined patient care delivery and practice efficiency changes using real-world data. Patients with diffuse large B-cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia who received a rituximab-containing regimen were eligible for the study.

Matasar touched on subcutaneous rituximab, the role it can play in treatment, the time savings associated with its use, and more.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

CancerNetwork spoke with Jun Gong, MD, a practicing medical oncologist who specializes in the treatment of genitourinary cancers at Cedars-Sinai Medical Center, regarding a perspective piece titled, “Cisplatin Neoadjuvant Chemotherapy in an Aging Population With Muscle-Invasive Bladder Cancer.”

Gong’s perspective focuses on an article published in the January issue of ONCOLOGY titled, “Use of Neoadjuvant Chemotherapy in Elderly Patients With Muscle-Invasive Bladder Cancer: A Population-Based Study, 2006-2017.”

In this conversation, Gong overviewed the research and touched on some of the clinically relevant findings. He then detailed his perspective and expanded on cisplatin-based chemotherapy, how age fits into the treatment equation, and where research should focus moving forward in muscle-invasive bladder cancer.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

CancerNetwork® recently spoke with Ofer Sharon, MD, CEO of OncoHost, about interim results from the prospective PROPHETIC trial to predict how patients with non–small cell lung cancer respond to immunotherapy.

Sharon first described OncoHost and the mission of this clinical stage precision oncology company. Then, he touched on the key details of this research, with a focus on the PROphet diagnostic platform at the center of this ongoing multicenter clinical trial, as well as what comes next for this research and OncoHost.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

CancerNetwork® spoke with Emily Smith, MD, of the Ellis Fishchel Cancer Center, University of Missouri, about a patient case published in the December issue of the journal ONCOLOGY titled, “Metastatic Basal Cell Carcinoma Arising From a Primary Cutaneous Carcinosarcoma.” Smith and colleagues detailed a case regarding a 56-year-old man who the team of care providers diagnosed with metastatic basal cell carcinoma arising from a carcinosarcoma.

In the conversation, Smith talked about what makes this patient case unique, the timeline of this specific patient’s disease and treatment, the rarity of basal cell carcinoma arising from a carcinosarcoma, and plenty more.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.